MBP8298 in Subjects with Secondary Progressive Multiple Sclerosis (SPMS)

Trial Status
Open for Enrollment

What is the Purpose of this Study?
To compare the clinical efficacy of 500 mg of a study medication, MBP8298 given intravenously every 6 months for a period of 2 years, to placebo, in patients dignosed with SPMS who are positive for the HLA DR2 and or DR4 haplotype, as well as compare the difference in relapse rates between the active and placebo groups. MBP is found in myelin which is a protective membrane found in the brain. MBP8298 may delay the worsening of disability in patients with SPMS.

Who is Eligible to Participate?
Patients aged 18-65 with a documented history of SPMS, with an absence of relapse in the 3 months prior to the baseline, who are HLA DR2 and or DR4 positive and who do not meet any exclusionary criteria which will be addressed in further detail by study coordinator

What is involved in this Study?
Patients who meet criteria will have a 1:1 treatment ratio of being injected with either MBP8298 or placebo once every 6 months for 18 months. During the course of the study you will have several brain MRIs, blood work and will be asked to fill out several questionnaires.

How long is the Study?
The study will be approximately 44 months long. You will be treated with medication for 24 months.

For More Information Contact: Lynne E. Flynn, CCRC, study coordinator, at 602-258-2863 or lynneflynn@pnal.net or call the Main line at 602-258-3354